Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

519 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance.
Johnson K, Leary PJ, Govaere O, Barter MJ, Charlton SH, Cockell SJ, Tiniakos D, Zatorska M, Bedossa P, Brosnan MJ, Cobbold JF, Ekstedt M, Aithal GP, Clément K, Schattenberg JM, Boursier J, Ratziu V, Bugianesi E, Anstee QM, Daly AK; LITMUS Consortium Investigators§; LITMUS Consortium Investigators. Johnson K, et al. Among authors: bedossa p. JHEP Rep. 2021 Nov 25;4(2):100409. doi: 10.1016/j.jhepr.2021.100409. eCollection 2022 Feb. JHEP Rep. 2021. PMID: 35072021 Free PMC article.
A comparison of fibrosis progression in chronic liver diseases.
Poynard T, Mathurin P, Lai CL, Guyader D, Poupon R, Tainturier MH, Myers RP, Muntenau M, Ratziu V, Manns M, Vogel A, Capron F, Chedid A, Bedossa P; PANFIBROSIS Group. Poynard T, et al. Among authors: bedossa p. J Hepatol. 2003 Mar;38(3):257-65. doi: 10.1016/s0168-8278(02)00413-0. J Hepatol. 2003. PMID: 12586290
C-reactive protein levels in relation to various features of non-alcoholic fatty liver disease among obese patients.
Zimmermann E, Anty R, Tordjman J, Verrijken A, Gual P, Tran A, Iannelli A, Gugenheim J, Bedossa P, Francque S, Le Marchand-Brustel Y, Clement K, Van Gaal L, Sørensen TIA, Jess T. Zimmermann E, et al. Among authors: bedossa p. J Hepatol. 2011 Sep;55(3):660-665. doi: 10.1016/j.jhep.2010.12.017. Epub 2011 Jan 14. J Hepatol. 2011. PMID: 21238518
Performance of biomarkers FibroTest, ActiTest, SteatoTest, and NashTest in patients with severe obesity: meta analysis of individual patient data.
Poynard T, Lassailly G, Diaz E, Clement K, Caïazzo R, Tordjman J, Munteanu M, Perazzo H, Demol B, Callafe R, Pattou F, Charlotte F, Bedossa P, Mathurin P, Ratziu V; FLIP consortium. Poynard T, et al. Among authors: bedossa p. PLoS One. 2012;7(3):e30325. doi: 10.1371/journal.pone.0030325. Epub 2012 Mar 14. PLoS One. 2012. PMID: 22431959 Free PMC article.
Lack of efficacy of an inhibitor of PDE4 in phase 1 and 2 trials of patients with nonalcoholic steatohepatitis.
Ratziu V, Bedossa P, Francque SM, Larrey D, Aithal GP, Serfaty L, Voiculescu M, Preotescu L, Nevens F, De Lédinghen V, Kirchner GI, Trunecka P, Ryder SD, Day CP, Takeda J, Traudtner K. Ratziu V, et al. Among authors: bedossa p. Clin Gastroenterol Hepatol. 2014 Oct;12(10):1724-30.e5. doi: 10.1016/j.cgh.2014.01.040. Epub 2014 Feb 12. Clin Gastroenterol Hepatol. 2014. PMID: 24530600 Clinical Trial.
519 results